| Literature DB >> 35186739 |
Jing Zhang1, Longchao Li1, Xia Zhe1, Min Tang1, Xiaoling Zhang1, Xiaoyan Lei1, Li Zhang1.
Abstract
OBJECTIVE: The aim of this study was to perform a meta-analysis to evaluate the diagnostic performance of machine learning(ML)-based radiomics of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) DCE-MRI in predicting axillary lymph node metastasis (ALNM) and sentinel lymph node metastasis(SLNM) in breast cancer.Entities:
Keywords: axillary lymph node metastasis; breast cancer; dynamic contrast-enhanced magnetic resonance imaging; machine learning; meta-analysis; radiomics
Year: 2022 PMID: 35186739 PMCID: PMC8854258 DOI: 10.3389/fonc.2022.799209
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Elements of the RQS and average rating achieved by the studies included in this meta-analysis.
| RQS scoring item | Interpretation | Average |
|---|---|---|
| Image Protocol | +1 for well documented protocols, +1 for publicly available protocols | 0.92 |
| Multiple Segmentations | +1 if segmented multiple times (different physicians, algorithms, or perturbation of regions of interest) | 0.62 |
| Phantom Study | +1 if texture phantoms were used for feature robustness assessment | 0.62 |
| Multiple Time Points | +1 multiple time points for feature robustness assessment | 0.08 |
| Feature Reduction | −3 if nothing, +3 if either feature reduction or correction for multiple testing | 3 |
| Non Radiomics | +1 if multivariable analysis with non-radiomics features | 0.54 |
| Biological Correlates | +1 if present | 0.08 |
| Cut-off | +1 if cutoff either pre-defined or at median or continuous risk variable reported | 0.15 |
| Discrimination and Resampling | +1 for discrimination statistic and statistical significance, +1 if resampling applied | 0.15 |
| Calibration | +1 for calibration statistic and statistical significance, +1 if resampling applied | 0.08 |
| Prospective | +7 for prospective validation within a registered study | 0 |
| Validation | −5 if no validation/+2 for internal validation/+3 for external validation/+4 two external validation | 0.38 |
| datasets or validation of previously published signature/+5 validation on ≥3 datasets from >1 institute | ||
| Gold Standard | +2 for comparison to gold standard | 2 |
| Clinical Utility | +2 for reporting potential clinical utility | 1.69 |
| Cost-effectiveness | +1 for cost-effectiveness analysis | 0.08 |
| Open Science | +1 for open-source scans, +1 for open-source segmentations, +1 for open-source code, +1 open-source representative segmentations and features | 1 |
Figure 1Flow diagram of study selection for meta-analysis.
Figure 2The risk of bias (left) and concerns for applicability (right) for each included study using QUADAS-2.
Baseline characteristic of included studies (1).
| Study | NO.patient | Magnetic field | Contrast agent | Phase | Data source | |
|---|---|---|---|---|---|---|
| Arefan, 2020 ( | 154 | Siemens | 3.0T | Magnevist | CE2 | Single institution |
| Chen, 2021 ( | 140 | GE | 3.0T | GD-DTPA | the strongest enhanced phase | Single institution |
| Cui, 2019 ( | 115 | Siemens | 3.0T | GD-DTPA | CE2 | Single institution |
| Han, 2019 ( | 411 | GE | 1.5T | Omniscan | CE1 | Single institution |
| Liu CL, 2019 ( | 163 | GE | 1.5T | Magnevist | One precontrast and four post-contrast phases | Single institution |
| Liu, 2019 ( | 62 | GE | 3.0T | GD-DTPA | the strongest enhanced phase | Single institution |
| Liu, 2020 ( | 164 | GE | 3.0T | GD-DTPA | the strongest enhanced phase | Single institution |
| Nguyen, 2020 ( | 357 | GE | 1.5T | gadopentetate dimeglumine /Gadavist | a single precontrast and four serial dynamic image | Two institution |
| Zhan, 2021 ( | 166 | Siemens | 3.0T | Omniscan | the strongest enhanced phase | Single institution |
| Shan,2019 ( | 196 | Siemens | 3.0T | Gd‐DTPA | CE2 | Single institution |
| Luo,2021 ( | 67 | Siemens | 3.0T | Gadolinium Diamine and Cardiamine Sodium | CE1 | Single institution |
| Ren, 2020 ( | 61 | GE | 1.5T | Gadavist, | CE1 | Single institution |
| Li, 2021 ( | 197 | Philips | 1.5T | Gadoteric acid meglumine salt | the early-and delayed-phase | Single institution |
CE1, the first postcontrast images; CE2, the second postcontrast phase.
Baseline characteristic of included studies (2).
| Study | Technique used for feature selection | Classification | Reference standard | Segmentation lesion | Tumor segmentation | Validation |
|---|---|---|---|---|---|---|
| Arefan, 2020 ( | LASSO | LDA, RF, NB,KNN, SVM | SLNB or ALND | 2D, 3D | semi-automatically | Test set, 10-fold cross-validation |
| Chen, 2021 ( | LASSO+10fold crossvalidation | LR | Pathology | 3D | manually | 10-fold cross-validation |
| Cui, 2019 ( | LASSO | SVM, KNN, LDA | SLNB or ALND | 2D, 3D, 4D | semi-automatically | cross-fold validation |
| Han, 2019 ( | LASSO+LOOCV | SVM | Pathology | 3D | manually | 6-fold validation |
| Liu CL, 2019 ( | LASSO+3fold crossvalidation | LR | Pathology | 3D | manually | 10-fold cross-validation |
| Liu, 2019 ( | The select K best+LASSO | SVM, Xgboost, LR | Pathology | 3D | manually | cross-fold validation |
| Liu, 2020 ( | LASS0 | LR | Pathology | 3D | manually | NOT REPORTED |
| Nguyen, 2020 ( | CNN | Pathology | 3D | semi-automatically | 10-fold cross-validation, Test set | |
| Zhan, 2021 ( | Spearman correlation analysis | SVM-RF | SLNB or ALND | 3D | manually | 5-fold validation |
| Shan,2019 ( | One-way analysis of variance+Wilcoxon rank sum test+correlation test+LASSO | LR | SLNB or ALND | 3D | manually | Confusion matrix |
| Luo,2021 ( | LASSO | linear discriminant analysis and leave-one-case-out-cross-validation | Pathology | 3D | manually | 10-fold cross-validation |
| Ren, 2020 ( | CNN | PET/CT | 2D | semi-automatically | 5-fold cross-validation | |
| Li, 2021 ( | Spearman+LASSO | LR | SLNB or ALND or Pathlogy | 3D | manually | 5-fold cross-validation |
LR, logistic regression; CNN, convolutional neural network; SVM, support vector machine; LDA, linear dis-criminant analysis; RF, random forest; NB, naive Bayes; KNN, K-nearest neighbor; LASSO, least absolute shrinkage and selection operator.
The results of subgroup analysis.
| Analysis | No. of study | Sensitivity | Specificity | PLR | NLR | DOR |
|---|---|---|---|---|---|---|
| Overall | 13 | 0.82 (0.75,0.87) | 0.83 (0.74,0.89) | 4.70 (3.01,7.35) | 0.22 (0.15,0.31) | 21.56 (10.60,43.85) |
| DL vs ML | ||||||
| ML | 11 | 0.80 (0.73,0.86) | 0.83 (0.76,0.88) | 4.45 (3.27,6.07) | 0.21 (0.14,0.32) | 22.82 (12.33,42.23) |
| DL | 2 | 0.84 (0.53,0.96) | 0.65 (0.31,0.89) | 2.45 (0.76,7.85) | 0.24 (0.04,1.45) | 9.95 (0.51,192.87) |
| Biopsy/vs Pathology | ||||||
| Biopsy | 6 | 0.85 (0.74,0.92) | 0.82 (0.75,0.88) | 4.50 (3.29,6.15) | 0.17 (0.09,0.31) | 29.17 (13.34,63.81) |
| Pathology | 7 | 0.77 (0.68,0.84) | 0.79 (0.62,0.89) | 3.63 (1.93,6.83) | 0.28 (0.16,0.52) | 13.95 (4.17,46.66) |
| 1.5T vs 3.0T | ||||||
| 3.0T | 8 | 0.82 (0.72,0.89) | 0.83 (0.76,0.88) | 4.62 (3.16,6.75) | 0.18 (0.10,0.34) | 30.09 (11.87,76.28) |
| 1.5T | 5 | 0.78 (0.69,0.85) | 0.76 (0.58,0.88) | 3.37 (1.74,6.55) | 0.26 (0.11,0.61) | 12.71 (3.56,45.41) |
| SLN vs ALN | ||||||
| ALN | 10 | 0.82 (0.75,0.87) | 0.81 (0.70,0.88) | 4.27 (2.60,7.03) | 0.20 (0.11,0.38) | 23.62 (8.99,62.04) |
| SLN | 3 | 0.71 (0.56,0.83) | 0.80 (0.68,0.88) | 3.74 (2.11,6.31) | 0.27 (0.16,0.46) | 12.17 (4.58,32,36) |
| Segmentation method | ||||||
| Semiautomatic | 5 | 0.82 (0.70,0.90) | 0.74 (0.56,0.87) | 3.26 (1.60,6.61) | 0.21 (0.07,0.60) | 15.95 (3.63,70.04) |
| Manually drawing | 8 | 0.80 (0.71,0.86) | 0.84 (0.75,0.90) | 4.82 (3.08,7.53) | 0.23 (0,16,0.33) | 23.59 (9.22,47.57) |
| different ROI | ||||||
| Lymph | 3 | 0.85 (0.68,0.94) | 0.81 (0.71,0.88) | 4.30 (2.59,7.15) | 0.17 (0.05,0.54) | 38.12 (7.06) |
| Breast Cancer | 10 | 0.79 (0.71,0.85) | 0.80 (0.67,0.89) | 4.02 (2.38,6.79) | 0.23 (0.13,0.42) | 17.62 (6.68,46.49) |
| Different algorithms of ML | ||||||
| SVM | 5 | 0.81 (0.70,0.89) | 0.76 (0.70,0.81) | 3.32 (2.64,4.17) | 0.20 (0.10,0.39) | 15.27 (7.49,31.13) |
| LR | 5 | 0.75 (0.65,0.82) | 0.88 (0.77,0.94) | 5.72 (3.13,10.44) | 0.29 (0.20,0.43) | 22.56 (9.15,55.62) |
| Different MR equipment | ||||||
| Siemens | 5 | 0.88 (0.77,0.94) | 0.82 (0.73,0.89) | 4.74 (2.93,7.66) | 0.14 (0.07,0.30) | 42.37 (11.97,149.91) |
| GE | 7 | 0.77 (0.68,0.84) | 0.75 (0.61,0.86) | 3.21 (1.79,5.75) | 0.28 (0.13,0.62) | 12.17 (4.03,36.75) |
PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; SVM,support vector machines; LR,logistic regression.
Figure 3Hierarchical summary receiver operating characteristic (SROC). curve of the diagnostic performance of ML-based radiomics of DCE-MRI in predicting ALNM in breast cancer.
Figure 4Forest plots of the sensitivity and specificity of ML-based radiomics of DCE-MRI in predicting ALNM in breast cancer. I2>50% indicated substantial heterogeneity in the diagnostic parameters across studies.
Figure 5Deeks funnel plot shows the likelihood of publication bias is low with a P value of 0.22. ESS, effective sample size.
Figure 6Fagan plot of ML-based radiomics models of DCE-MRI in predicting ALNM in breast cancer.